Nature Communications (Feb 2021)
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
- Arvind Singh Mer,
- Emily M. Heath,
- Seyed Ali Madani Tonekaboni,
- Nergiz Dogan-Artun,
- Sisira Kadambat Nair,
- Alex Murison,
- Laura Garcia-Prat,
- Liran Shlush,
- Rose Hurren,
- Veronique Voisin,
- Gary D. Bader,
- Corey Nislow,
- Mattias Rantalainen,
- Soren Lehmann,
- Mark Gower,
- Cynthia J. Guidos,
- Mathieu Lupien,
- John E. Dick,
- Mark D. Minden,
- Aaron D. Schimmer,
- Benjamin Haibe-Kains
Affiliations
- Arvind Singh Mer
- Princess Margaret Cancer Centre, University Health Network
- Emily M. Heath
- Princess Margaret Cancer Centre, University Health Network
- Seyed Ali Madani Tonekaboni
- Princess Margaret Cancer Centre, University Health Network
- Nergiz Dogan-Artun
- Princess Margaret Cancer Centre, University Health Network
- Sisira Kadambat Nair
- Princess Margaret Cancer Centre, University Health Network
- Alex Murison
- Princess Margaret Cancer Centre, University Health Network
- Laura Garcia-Prat
- Princess Margaret Cancer Centre, University Health Network
- Liran Shlush
- Department of Immunology, Weizmann Institute of Science
- Rose Hurren
- Princess Margaret Cancer Centre, University Health Network
- Veronique Voisin
- The Donnelly Centre, University of Toronto
- Gary D. Bader
- The Donnelly Centre, University of Toronto
- Corey Nislow
- Faculty of Pharmaceutical Sciences, The University of British Columbia
- Mattias Rantalainen
- Karolinska Institute
- Soren Lehmann
- Karolinska Institute
- Mark Gower
- The Hospital for Sick Children
- Cynthia J. Guidos
- The Hospital for Sick Children
- Mathieu Lupien
- Princess Margaret Cancer Centre, University Health Network
- John E. Dick
- Princess Margaret Cancer Centre, University Health Network
- Mark D. Minden
- Princess Margaret Cancer Centre, University Health Network
- Aaron D. Schimmer
- Princess Margaret Cancer Centre, University Health Network
- Benjamin Haibe-Kains
- Princess Margaret Cancer Centre, University Health Network
- DOI
- https://doi.org/10.1038/s41467-021-21233-0
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Molecular heterogeneity of acute myeloid leukaemia (AML) across patients is a major challenge for prognosis and therapy. Here, the authors show that NPM1 mutated AML is a heterogeneous class, consisting of two subtypes which exhibit distinct molecular characteristics, differentiation state, patient survival and drug response.
